

Supplemental Online Content


Mendell JR, Al-Zaidy S, Lehman K, et al. Five-year extension results of the phase I START trial of onasemnogene abeparvovec in spinal muscular atrophy. *JAMA Neurol*. Published online May 17, 2021. doi:10.1001/jamaneurol.2021.1272

eFigure. Probability of permanent ventilation-free survival.

eReferences.

This supplemental material has been provided by the authors to give readers additional information about their work.

eFigure. Probability of permanent ventilation-free survival.



Permanent ventilation-free survival is provided for the therapeutic-dose cohort of the START LTFU long-term follow-up study compared with natural history controls from the PNCR study.¹

LTFU, long-term follow-up; PNCR, Pediatric Neuromuscular Clinical Research.

eReferences

1. Finkel RS, McDermott MP, Kaufmann P, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. *Neurology*. 2014;83(9):810–817.